Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients

被引:104
作者
Fisher, Cynthia E. [1 ,2 ]
Knudsen, Janine L. [1 ]
Lease, Erika D. [1 ,3 ]
Jerome, Keith R. [2 ,4 ]
Rakita, Robert M. [1 ]
Boeckh, Michael [1 ,2 ]
Limaye, Ajit P. [1 ]
机构
[1] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA
[3] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA
[4] Univ Washington, Dept Lab Med, Virol Div, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
cytomegalovirus; solid organ transplant; ganciclovir resistance; risk factors; outcomes; RAPID DETECTION; DISEASE; EMERGENCE; PROPHYLAXIS; FOSCARNET; SAMPLES; IMPACT; UL97; ERA;
D O I
10.1093/cid/cix259
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Ganciclovir-resistant (ganR) cytomegalovirus (CMV) is an emerging and important problem in solid organ transplant (SOT) recipients. Only through direct comparison of ganR- and ganciclovir-sensitive (ganS) CMV infection can risk factors and outcomes attributable specifically to ganciclovir resistance appropriately be determined. Methods. We performed a retrospective, case-control (1: 3) study of SOT recipients with genotypically confirmed ganR-CMV (n = 37) and ganS-CMV infection (n = 109), matched by donor/recipient CMV serostatus, year and organ transplanted, and clinical manifestation. We used chi(2) (categorical) and Mann-Whitney (continuous) tests to determine predisposing factors and morbidity attributable to resistance, and Kaplan-Meier plots to analyze survival differences. Results. The rate of ganR-CMV was 1% (37/3467) overall and 4.1% (32/777) among CMV donor-positive, recipient-negative patients, and was stable over the study period. GanR-CMV was associated with increased prior exposure to ganciclovir (median, 153 vs 91 days, P<.001). Eighteen percent (3/17) of lung transplant recipients with ganR-CMV had received <6 weeks of prior ganciclovir (current guideline-recommended resistance testing threshold), and all non-lung recipients had received = 90 days (median, 160 [range, 90-284 days]) prior to diagnosis of ganR-CMV. GanR-CMV was associated with higher mortality (11% vs 1%, P = .004), fewer days alive and nonhospitalized (73 vs 81, P = .039), and decreased renal function (42% vs 19%, P = .008) by 3 months after diagnosis. Conclusions. GanR-CMV is associated with longer prior antiviral duration and higher attributable morbidity and mortality than ganS-CMV. Upcoming revised CMV guidelines should incorporate organ transplant-specific thresholds of prior drug exposure to guide rational ganR-CMV testing in SOT recipients. Improved strategies for prevention and treatment of ganR-CMV are warranted.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 20 条
[1]   Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection [J].
Avery, Robin K. ;
Arav-Boger, Ravit ;
Marr, Kieren A. ;
Kraus, Edward ;
Shoham, Shmuel ;
Lees, Laura ;
Trollinger, Brandon ;
Shah, Pali ;
Ambinder, Rich ;
Neofytos, Dionysios ;
Ostrander, Darin ;
Forman, Michael ;
Valsamakis, Alexandra .
TRANSPLANTATION, 2016, 100 (10) :E74-E80
[2]   Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients [J].
Bhorade, SM ;
Lurain, NS ;
Jordan, A ;
Leischner, J ;
Villanueva, J ;
Durazo, R ;
Creech, S ;
Vigneswaran, WT ;
Garrity, ER .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2002, 21 (12) :1274-1282
[3]   Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR [J].
Boeckh, M ;
Huang, M ;
Ferrenberg, J ;
Stevens-Ayers, T ;
Stensland, L ;
Nichols, WG ;
Corey, L .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (03) :1142-1148
[4]   Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance [J].
Castor, Jared ;
Cook, Linda ;
Corey, Lawrence ;
Jerome, Keith R. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2007, 45 (08) :2681-2683
[5]   Approach to drug-resistant cytomegalovirus in transplant recipients [J].
Chou, Sunwen .
CURRENT OPINION IN INFECTIOUS DISEASES, 2015, 28 (04) :293-299
[6]   Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes [J].
Eid, Albert J. ;
Arthurs, Supha K. ;
Deziel, Paul J. ;
Wilhelm, Mark P. ;
Razonable, Raymund R. .
CLINICAL TRANSPLANTATION, 2008, 22 (02) :162-170
[7]   Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients [J].
Fisher, C. E. ;
Alexander, J. ;
Bhattacharya, R. ;
Rakita, R. M. ;
Kirby, K. A. ;
Boeckh, M. ;
Limaye, A. P. .
TRANSPLANT INFECTIOUS DISEASE, 2016, 18 (03) :372-380
[9]   Updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation [J].
Kotton, Camille N. ;
Kumar, Deepali ;
Caliendo, Angela M. ;
Asberg, Anders ;
Chou, Sunwen ;
Danziger-Isakov, Lara ;
Humar, Atul .
TRANSPLANTATION, 2013, 96 (04) :333-360
[10]   The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation [J].
Kruger, RM ;
Shannon, WD ;
Arens, MQ ;
Lynch, JP ;
Storch, GA ;
Trulock, EP .
TRANSPLANTATION, 1999, 68 (09) :1272-1279